Sir -We read with interest the article by Nakamura et al. (Br. J. Cancer (1992) 66, [20] [21] [22] [23] [24] [25] [26] describing the generation of large numbers of CD4+CD45RO+ helper/killer T-cells for potential use in adoptive tumour immunotherapy. It is these cells that form the basis for autolymphocyte therapy (ALT). As previously reported, ALT is adoptive tumour immunotherapy based upon the infusion of CD4+CD45RO+ (memory) T-cells that are activated ex vivo by low doses of the mitogenic monoclonal antibody OKT3, in combination with a previously prepared mixture of autologous cytokines (Celis et al., 1991) . We have demonstrated that ex vivo activation of murine splenocytes results in the generation of tumourspecific T-cells with a memory phenotype . In addition, ex vivo depletion of CD45RO+ T-cells from the autolymphocyte preparation markedly impairs ex vivo lysis of autologous tumour targets (Gold et al., 1993) . Monthly infusions of autolymphocytes and daily oral cimetidine has been shown to be active in patients with metastatic renal cell cancer (Osband et al., 1990; Lavin et al., 1992) . Similar to ALT, the cells generated by the methodology of Nakamura et al. were made up mostly of the CD45RO+ subset of CD4+ T-cells.
There are however, two important distinctions and issues that need to be addressed regarding both autolymphocytes and the CD4+ helper/killer T-cells of the report by Nakamura et al. The first is that autolymphocytes are derived ex vivo from activation of unseparated peripheral blood lymphocytes (PBL). As stated, it has been shown that nonspecific ex vivo activation of murine splenocytes results in the generation of autolymphocytes that are tumour-specific and that high levels of interleukin (IL)-1 rather than IL-2 in human ex vivo cell cultures correlate with improved clinical efficacy (Osband et al., 1990; Lavin et al., 1992) . Therefore, it may not be necessary to separate the CD4+ T-cell subset from PBL, and in fact may be clinically advantageous and physiologic to activate and then infuse memory T-cells as part of a heterogeneous cell population for adoptive tumour immunotherapy (Panzer et al., 1990) . The second distinction involves the actual number of cells to be infused. A commonly held belief in adoptive tumour immunotherapy is that 'more is better'. That is, the greater number of cells that one wishes to infuse, the better for the patient. However, this may not be the case as it has been demonstrated with ALT that more cells are not necessarily better (Ross & Osband, 1989) . Indeed, patients who receive autolymphocytes above a certain threshold value may actually do worse than those receiving less cells. It is possible that a large number of autolymphocytes or CD4+ helper/ killer T-cells may cause an 'anti-idiotypic' reaction with concommitant generation of suppressor cells to down-regulate the anti-tumour response. In addition, if the CD4+ T-cell population is indeed the orchestrator of the anti-tumour response, then a small number of cells may be all that is required to initiate effective therapy. In summary while the report by Nakamura et al. re-enforces the use of CD4+ T-cells in adoptive tumour immunotherapy, it may not be necessary to separate the CD4+ T-cells from PBL or require large numbers of cells for an effective anti-tumour response.
